Liraglutide: New results in the treatment of type 2 diabetes mellitus

Drugs of Today

Volumn 48, Issue SUPPL. B, 2012, Pages 1-17

  Mateos, J L ^a   Wajchenberg, B L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIPID; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN; PYRAZINE DERIVATIVE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIAZOLE DERIVATIVE;

BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; LONG TERM CARE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; DOSE RESPONSE; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PYRAZINES; SULFONYLUREA COMPOUNDS; TRIAZOLES;

EID: 84865619716     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48(Suppl.A).1876681     Document Type: Review

References (81)

1. Huang É, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the US. Diabetes Care. 2009; 32:2225-2229.
2. US Department of Health and Human Services, National Diabetes Information Clearinghouse. National Diabetes Statistics, 2007. NIH Publication No. 08-3892. Em: http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM-Statistics. Last updated: June 2008. Accessed October 19, 2010.
3. International Diabetes Federation. Diabetes and impaired glucose tolerance: global burden: prevalence and projections, 2010 and 2030. International Diabetes Federation Website. Em: http://www.diabetesatlas.org /content/diabetesand-impaired-glucose-tolerance. Accessed October 19, 2010.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203.
5. Lin E, Sun Z. Current views on type 2 diabetes. J Endocrinol. 2010; 204:1-11.
6. DeFronzo RA. Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58:773-795.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
8. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes - a comprehensive review. Diabetes Technol Therapeutics 2010; 12:11-24.
9. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. Ann Intern Med 2007; 147:386-399. (Pubitemid 351664540)
10. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clinical Therapeutics 2011; 33:528-576.
11. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM. 2003; 96:281-288. (Pubitemid 36432387)
12. DeFronzo R, Banerji MA, Bray G, et al. Reduced insulin secretion/insulin resistance (disposition) index is the primary determinant of glucose intolerance in the pre-diabetic state: results from ACT NOW. Paper presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
13. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995; 44: 1249-1258.
14. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427-2443. (Pubitemid 44903747)
15. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycaemic controle, weight gain, and hypoglycaemia in type 2 diabetes. JAMA 2010; 303:1410-1418.
16. Cernea S, Raz MD. Therapy in the early stage: incretins. Diabetes Care 2011; 34 (Suppl 2):S264-S271.
17. Elrick H, Stimmler L, Hlad CJ Jr, Arai E. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964; 24:1076-1082.
18. Holst JJ, LaSalle JR. An overview of incretin hormones. J Fam Prac. 2008; 57:S4-S9.
19. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3:153-165.
20. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002; 282:G424-G431. (Pubitemid 34651657)
21. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999; 276:R1541-R1544. (Pubitemid 29249681)
22. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003; 17:161-171. (Pubitemid 36183142)
23. Girard J. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab. 2008; 34:550-559.
24. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29:46-52. (Pubitemid 16162741)
25. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose stimulated insulin secretion: effects on - cell sensitivity in Type 2 and nondiabetic subjects. Diabetes 2003; 52:380-386. (Pubitemid 36173193)
26. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008; 57:678-687.
27. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009; 122:S3-S10.
28. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009; 32:762-768.
29. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374:39-47.
30. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function Diabetes. 2010; 59:1117-1125.
31. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and metaanalysis. JAMA 2007, 298:194-206. (Pubitemid 47057766)
32. Agersø H, Jensen LB, Elbrønd B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202. (Pubitemid 34208381)
33. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669. (Pubitemid 30304999)
34. Vilsboll, T. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88:220-224. (Pubitemid 36115169)
35. Kapitza C, Flint A, Spitzer H, Hindsberger C, Zdravkovic M. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. (Abstr). Diabetes. 2008; 57:A593.
36. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010; 38: 1944-1953.
37. Jacobsen L, Hindsberger C, Robson, R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analog liraglutide. Br J Clin Pharmacol. 2009; 68:898-905.
38. McGill J. Insights from the liraglutide clinical development program - the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med. 2009; 121:16-25.
39. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analog liraglutide. Diabetes. 2007; 56:A145.
40. Malm-Erjelfalt M, Ekblom M, Brondsted L, et al. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. (Abstr). Diabetes. 2008; 57:A130.
41. Jacobsen LV, Brøndsted L, Vouis J, Zdravkovic M. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug. Presented at: 68th Annual Scientific Sessions of the American Diabetes Association (ADA); June 6-10, 2008; San Francisco, California, USA.
42. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, doubleblind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78:675-688. (Pubitemid 41773643)
43. Rolin B, Larsen MO, Gotfredsen CF. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283:E745-E752.
44. Sturis J, Gotfredsen CF, Rømer J. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol. 2003; 140:123-132. (Pubitemid 37175838)
45. Bregenholt S, Møldrup A, Blume N. The long-acting glucagon-like peptide 1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005; 330:577-584. (Pubitemid 40417684)
46. Shimoda M, Kanda E, Hamamoto S, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011; 54:1098-1108.
47. Marre M, Shaw J, Brändle M, Bebakar WM, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26:268-278.
48. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008; 25:152-156. (Pubitemid 351293400)
49. Vilsbøll T, Knop FK, Christensen M, et al. Weight-lowering efficacy of glucagon-like peptide-1 receptor agonists: a meta-analysis. Presented at: 71st Annual Scientific Sessions of the American Diabetes Association (ADA); June 24-28, 2011; San Diego, California, USA.
50. Visbøll T, Zdravkovik M, Le-Thi T. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care. 2007; 30:1608-1610. (Pubitemid 46871185)
51. Colagiuri S, Frid A, Zdravkovic M, Le-Thi T, Vaag A. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Diabetes. 2008; 57:A164-A165.
52. Rodbard HW, Jellinger PS, Davidson JA, et al. Glycemic control algorithm. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15(6): 513-655.
53. st Annual Scientific Sessions of the American Diabetes Association (ADA); June 24-28, 2011; San Diego, California, USA.
54. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002; 51:424-429. (Pubitemid 34764798)
55. Harder H, Nielsen L, Thi TD, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004; 27:1915-1921. (Pubitemid 38989232)
56. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003; 52:1786-1791. (Pubitemid 36792471)
57. Taniguchi E, Mori E, Sezaki K. The effect of the human GLP-1 analogue liraglutide on 24-hour glycemic variations in Japanese type 2 diabetic, obese patients as assessed by continuos glucose monitoring (CGM). Presented at: 71st Annual Scientific Sessions of the American Diabetes Association (ADA); June 24-28, 2011,; San Diego, California, USA.
58. Madsbad S, Schmitz OU, Ranstam J, et al. Improved glycemic controle with não weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27:1335-1342. (Pubitemid 38679980)
59. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago OU. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic controle and bodyweight in subjects with type 2 diabetes. Diabet Med 2005; 22:1016-1023. (Pubitemid 41025998)
60. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD- 3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373:473-81.
61. Bode BW, Testa MA, Magwire M, et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2011; 12:604-612.
62. Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic controle and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13:348-356.
63. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (LEAD-2). Diabetes Care 2009; 32:84-90.
64. Pratley R, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-56.
65. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65:397-407.
66. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32:1224-30.
67. Russell-Jones D, Vaag A, Scmitz OU, et al. Liraglutine vs insulin glargine and placebo combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU):a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
68. Buse JB, Sesti G, Schmidt WE et al. Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33:1300-3.
69. Schmidt WE, Christiansen JS, Hammer M, et al. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med 2011; 28:715-723.
70. Wolfe G, King A. Clinical experience with liraglutide: the first 100 patients. Presented at: 71st Annual Scientific Sessions of the American Diabetes Association (ADA); June 24 - 28, 2011; San Diego, California, USA.
71. Parks M and Rosebraugh C. Weighing risks and benefits of liraglutide - The FDA's review of a new antidiabetic therapy. N Eng J Med 2010; 362:774-7.
72. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151:1473-86.
73. Ampudia-Balsco FJ, Calvo Gómez C, Cos Claramunt X, et al. Liraglutida en el tratamiento del diabetes tipo 2: recomendaciones para una mejor selección de los pacientes desde uma visión multidisciplinar. SEMG 2010; 130:549-559.
74. Victoza. Summary of Product Characteristics, the electronic Medicines Compendium (eMC). Available from: http://emc.medicines.org.uk/medicine/21986/ SPC/ [last accessed April 2010]
75. AACE/ACE Consensus Statement. American Association of Clinical Endocrinologists/ American College of Endocrinology. Consensus Panel on Type 2 diabetes mellitus an algorithm for glycemic control. Endocrine Pract 2009; 15:541-559.
76. Gallwitz B, Vaag A, Falahati A, et al. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2010; 64:267-76.
77. Schmitz OU, Russell-Jones D, Shaw J, et al. Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline. Diabetologia 2008; 51 (Suppl.1):S354-S5.
78. Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction inmice. Diabetes 2009; 58: 975-983.
79. Nikolaidis A, Mankad S, Sokos GG et al. Effects of glucagon- like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-965. (Pubitemid 38282847)
80. Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1(GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:824-829. (Pubitemid 47268274)
81. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies. Diabetes Vasc Dis Res 2011. Available in: dvr.sagepub.com